As the number of patients requiring Renal Replacement Therapy steadily increases, it’s important to identify treatments that are both clinically beneficial and cost-effective.

The reduced direct cost of home or self-care haemodialysis is influenced by savings in nursing resource and hospital transport. SC+ reduces the cost burden to healthcare providers and alleviates in-centre capacity constraints.

Quanta’s unique approach to dialysis addresses a large and rapidly growing global dialysis (products and services) market worth a total of $76 billion currently.1

Estimated to grow to:

4 million
By 2020

24,166
patients
in the UK alone during 2014

Market Potential

Who We Are

Founded in 2008. Privately owned and based in Alcester, UK.

Investors
• Air Liquide
• b-to-v Partners AG
• IMI
• Kuwait Life Sciences Company
• Stage Capital
• Seroba Life Sciences
• Sevenure Partners
• Wellington Partners

Management
John E. Milad
Chief Executive Officer
Willem Baralt
Chief Financial Officer
Peter Hoyer
Chief Commercial Officer
Prof. Clive Buckberry
Chief Technology Officer
Amit Bose
Chief Engineer
Rolf Wildeman
Chief of Operations
Martin Newman
Chief of Quality and Regulatory Affairs

References
1. SC-01099 Quanta Supporting Literature.
3. 18th Annual Report, UK Renal Registry.
End Stage Renal Disease and Haemodialysis

Lifestyle, diet and an ageing population are negatively impacting renal health, with End Stage Renal Disease affecting millions of patients worldwide. Haemodialysis is a lifesaving treatment delivered to over 2.6 million people globally.\(^1\) A number of studies have shown that 30-40% of patients are capable of self-dialysis, and that regular treatment improves patient outcomes and quality of life.\(^2\)

A major factor limiting growth of self-care and home haemodialysis is the lack of easy to use, flexible and cost effective dialysis systems. SC+ addresses these issues, giving patients the best opportunity to take greater control of their treatment.

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in a range of care settings. SC+ is designed with you in mind. Whether you’re a patient, provider or practitioner, SC+ provides solutions through innovative design.

Our mission at Quanta is to improve the lives of patients by using innovative design and cutting edge technology to provide affordable solutions in renal care.

Designed With Patients In Mind

- Disposable cartridges allow for quick and easy set up
- Logical screen flow allowing you to focus on treatment tasks
- Compact and less intrusive design
- Supports traditional treatment regimens commonly used in-centre

1. https://www.quantahealthcare.com
2. https://www.hemodialysis.com